SCHEMBL2115244

SCHEMBL2115244

CC(N)C(=O)N1CCC[C@@H]1C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 6/20 0.64
REN P00797 4/20 0.64
KDM4E B2RXH2 1/20 0.64
F2 P00734 1/20 0.64
LMNA P02545 1/20 0.64
LTA4H P09960 1/20 0.64
MAPT P10636 1/20 0.64
PEPD P12955 1/20 0.64
ALOX15 P16050 1/20 0.64
PTGS1 P23219 1/20 0.64
HTR2A P28223 1/20 0.64
PTGS2 P35354 1/20 0.64
HRH1 P35367 1/20 0.64
THPO P40225 1/20 0.64
PMP22 Q01453 1/20 0.64
HSD17B10 Q99714 1/20 0.64
ACE2 Q9BYF1 1/20 0.64
DPP4 P27487 3/20 0.58
FAP Q12884 2/20 0.58
DPP7 Q9UHL4 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7271951 1.00 ACE (0.64) ACERENKDM4EF2LMNA
SCHEMBL152403 1.00 ACE (0.64) ACERENKDM4EF2LMNA
SCHEMBL8316371 1.00 ACE (0.64) ACERENKDM4EF2LMNA
SCHEMBL9164453 1.00 ACE (0.64) ACERENKDM4EF2LMNA
SCHEMBL19824765 1.00 ACE (0.64) ACERENKDM4EF2LMNA
SCHEMBL593691 1.00 ACE (0.64) ACERENKDM4EF2LMNA
SCHEMBL2115246 1.00 ACE (0.64) ACERENKDM4EF2LMNA
Hydrogen Sulfide SCHEMBL28780209 0.98 ACE (0.62) ACERENKDM4EF2LMNA
Water SCHEMBL11063395 0.98 ACE (0.62) ACERENKDM4EF2LMNA
Hydrogen Sulfide SCHEMBL28780210 0.98 ACE (0.62) ACERENKDM4EF2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1323730-B1 NOVEL POLYPEPTIDES AND ANTI-HIV DRUGS CONTAINING THE SAME BIOKINE THERAPEUTICS LTD (IL) 2010-04-21 EP claimed
US-20100055088-A1 CXCR4 Antagonists for Wound Healing and Re-Epithelialization HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) 2010-03-04 US claimed
EP-1898943-A2 CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION Hadasit Medical Research Services & Development Ltd. (IL) 2008-03-19 EP claimed
WO-2006126188-A2 CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) 2006-11-30 WO claimed
US-20040116655-A1 Novel polypeptides and anti-hiv drugs containing the same BIOKINE THERAPEUTICS LTD. (IL) 2004-06-17 US claimed
EP-1323730-A1 NOVEL POLYPEPTIDES AND ANTI-HIV DRUGS CONTAINING THE SAME SEIKAGAKU CORPORATION (JP) 2003-07-02 EP claimed
EP-3011961-B1 4F-BENZOYL-TN14003 FOR THE MOBILISATION OF HEMATOPOIETIC PROGENITOR CELLS IN VIEW OF TRANSPLANTATION BIOKINE THERAPEUTICS LTD (IL) 2020-11-11 EP disclosed
EP-2841084-B1 CXCR4 ANTAGONIST PEPTIDE FOR USE IN THE TREATMENT OF LARGE CELL LUNG CANCER BIOKINE THERAPEUTICS LTD (IL) 2018-05-30 EP disclosed
US-9439942-B2 Peptides and use thereof in the treatment of large cell lung cancer BIOKINE THERAPEUTICS LTD. (IL) 2016-09-13 US disclosed
US-9427456-B2 Peptide therapy for increasing platelet levels BIOKINE THERAPEUTICS LTD. (IL) 2016-08-30 US disclosed
EP-3011961-A1 4F-benzoyl-TN14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation Biokine Therapeutics LTD. (IL) 2016-04-27 EP disclosed
EP-2942059-A1 4F-BENZOYL-TN14003 FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA Biokine Therapeutics LTD. (IL) 2015-11-11 EP disclosed
US-9034814-B2 CXCR4 antagonists for wound healing and re-epithelialization HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) 2015-05-19 US disclosed
WO-2008075369-A2 T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR BONE MARROW RECOVERY BIOKINE THERAPEUTICS LTD. (IL) 2008-06-26 WO disclosed
EP-1898943-A2 CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION Hadasit Medical Research Services & Development Ltd. (IL) 2008-03-19 EP disclosed
WO-2006126188-A2 CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) 2006-11-30 WO disclosed
US-20060264605-A1 Polypeptides having anti-HIV activity and compositions comprising same BIOKINE THERAPEUTICS LTD. (IL) 2006-11-23 US disclosed
US-7138488-B2 Polypeptides having anti-HIV activity and compositions comprising same BIOKINE THERAPEUTICS LTD. (IL) 2006-11-21 US disclosed
US-20040116655-A1 Novel polypeptides and anti-hiv drugs containing the same BIOKINE THERAPEUTICS LTD. (IL) 2004-06-17 US disclosed
EP-1323730-A1 NOVEL POLYPEPTIDES AND ANTI-HIV DRUGS CONTAINING THE SAME SEIKAGAKU CORPORATION (JP) 2003-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100055088-A1 CXCR4 Antagonists for Wound Healing and Re-Epithelialization CXCR4, CXCL12, CXCR5 ACE 3845/4885REN 2024/4885KDM4E 3800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.